NCT Number: NCT00680108
A Study to Determine the Safety and Tolerability of Escalating Doses of INS365 Ophthalmic Solution
The purpose of this study is to evaluate the safety and tolerability of INS365 Ophthalmic Solution when applied topically as eyedrops in patients with mild to moderate dry eye disease.
Looking for future studies?
Notify MeKey information
Study type
Interventional
Phase
Phase 2
Who can participate
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Best corrected visual acuity 20/40 in each eye
- 2 out 5 specified symptoms
- Corneal fluorescein staining score greater than or equal to 3 out of 15
Exclusion criteria
- Unable to stop concomitant medications
- Have had intraocular surgery in previous 90 days
- Have excluded systemic or ocular disease
- Wear contact lenses and are not willing to remove them
- Have intraocular pressure greater than 22 mg Hg
Treatment and study plan
Primary outcomes
-
Evaluation of adverse events
-
Ocular symptomatology
-
Visual acuity
-
Biomicroscopy
-
Ophthalmoscopy
Secondary outcomes
-
Unanesthetized Schirmer test
Sponsors and collaborators
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Registry information
Official study title
A Double-Masked, Randomized, Placebo-Controlled, Rising-Dose Study of Multiple Ocular Instillations of INS365 Ophthalmic Solution in Patients With Mild to Moderate Dry Eye Disease.
Important dates
- Study start
- 1999
- Primary completion
- 2000
- Study completion
- 2000
- First posted
- May 19, 2008
- Registry last updated
- Aug 27, 2015
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
An Evaluation of the Safety and Tolerability of Ocular Lubricants
NCT07238699
Dry Eye Disease, Dry Eye Syndromes
Sydney, New South Wales, Australia
View Trial DetailsA Study to Explore Signs, Symptoms, and Biomarkers in Dry Eye Disease Participants Following Anti-inflammatory Treatment
NCT07025811
Dry Eye Disease, Dry Eye Syndromes
Newport Beach, California, United States
View Trial DetailsA Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye Disease
NCT07128628
Dry Eye Disease, Dry Eye Syndromes
Phoenix, Arizona, United States
View Trial DetailsEvaluating the Safety, Tolerability, and Efficacy of GRF312 5% in Participants With Dry Eye Disease (DED).
NCT07264517
Autoimmune Diseases, Dry Eye Disease
Glendale, California, United States
View Trial Details